Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development
Liquidia Technologies has appointed Dr. Gerald M. O’Brien as Vice President of Pulmonary Clinical Development, effective immediately. With 25 years of experience in pulmonary critical care, Dr. O’Brien aims to enhance Liquidia's efforts in treating pulmonary arterial hypertension (PAH). Previously, he led the PRIMEx trial at Complexa Inc. Liquidia focuses on developing innovative products using its proprietary PRINT® technology, specifically for PAH and post-operative pain management.
- Appointment of Dr. Gerald M. O’Brien could strengthen clinical development for PAH treatments.
- Dr. O’Brien's extensive experience in pulmonary care may enhance the company's credibility in the market.
- Dependence on clinical trials for product development carries inherent risks and uncertainties.
- Potential delays in clinical development timelines could impact overall company strategy.
Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care
RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced the appointment of Dr. Gerald M. O’Brien as Vice President, Pulmonary Clinical Development, effective immediately.
“Jerry is an accomplished pulmonary critical care expert who has dedicated his career to the treatment of patients and the advancement of respiratory therapeutics that address unmet medical needs. Jerry’s expertise further augments our team’s ability to support pulmonary arterial hypertension (PAH) patients and the PAH community as a whole,” said Tushar Shah, MD, Chief Medical Officer and Head of R&D at Liquidia. “In this newly created position, Jerry will take a leading role in clinical development efforts for the company’s pulmonary programs. We welcome Jerry to the Liquidia team and look forward to his contributions to our near-term deliverables and long-term strategy.”
Dr. O’Brien joins Liquidia with 25 years of medical practice experience including 10 years in an academic medical center and 15 years in a large community-based private practice. His career has been centered around the treatment of patients with advanced lung disease, initially as founder of the TEMPLE Lung Transplant Program and Lung Volume Reduction Program and then as founder and director of the Pulmonary Hypertension Center in Delaware. Dr. O’Brien was also the founder of the Interventional Pulmonary Program at the Helen Graham Cancer Center, a National Cancer Institute Community Cancer Center in Delaware.
Prior to Liquidia, Dr. O’Brien was the Vice President of Development at Complexa Inc., where he led the execution of PRIMEx, a phase 2/3 trial for the treatment of PAH. He also previously served as the Senior Director of Medical Affairs and the Director of Medical Affairs at AstraZeneca and Bayer Pharmaceuticals, respectively.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or two petitions for inter partes review with the Patent Trial and Appeal Board, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our and Liquidia Corporation’s filings with the Securities and Exchange Commission, including the risk that our proposed acquisition of RareGen, LLC is not consummated or that the expected benefits and synergies from the proposed acquisition are not realized, the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com
Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
What is Liquidia's focus with the appointment of Dr. O’Brien?
What experience does Dr. O’Brien bring to Liquidia?
What are Liquidia's main product candidates?
How does Liquidia’s PRINT® technology benefit its products?
What are the risks associated with Liquidia's clinical trials?
